Stock Events

NOVAVAX INC NOVAVAX ORD SHS 

$11.9
835
-$2.75-18.8% Friday 18:12

Statistics

Day High
14.7
Day Low
13.18
52W High
27
52W Low
3.53
Volume
199,351
Avg. Volume
157,217
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6NovExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-3.46
-1.75
-0.04
1.67
Expected EPS
-0.903333
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0A3S.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap29.75B
Moderna is a direct competitor in the mRNA vaccine space, particularly for COVID-19, similar to Novavax's efforts in vaccine development.
Pfizer
PFE
Mkt Cap164.39B
Pfizer, in collaboration with BioNTech, developed a COVID-19 vaccine that competes directly with Novavax's COVID-19 vaccine.
BioNTech
BNTX
Mkt Cap20.98B
BioNTech partners with Pfizer for the COVID-19 vaccine, making it a direct competitor to Novavax in the vaccine market.
Johnson & Johnson
JNJ
Mkt Cap399.26B
Johnson & Johnson developed a single-shot COVID-19 vaccine, competing in the same pandemic response market as Novavax.
Astrazeneca
AZN
Mkt Cap271.67B
AstraZeneca developed a COVID-19 vaccine using a different technology but competes in the same global vaccine market as Novavax.
Sanofi
SNY
Mkt Cap141.43B
Sanofi is working on COVID-19 vaccine candidates and influenza vaccines, positioning it as a competitor in the broader vaccine market.
GSK
GSK
Mkt Cap89.55B
GlaxoSmithKline, with its extensive vaccine portfolio and efforts in COVID-19 vaccine development, competes in the same space as Novavax.
CureVac N.V.
CVAC
Mkt Cap704.35M
CureVac competes in the mRNA vaccine space, focusing on COVID-19 and other diseases, similar to Novavax's approach.
Novavax
NVAX
Mkt Cap1.98B
Dynavax offers adjuvants for vaccines, making it a competitor in the broader vaccine development and enhancement market.
Dynavax Technologies
DVAX
Mkt Cap1.47B
Dynavax offers adjuvants for vaccines, making it a competitor in the broader vaccine development and enhancement market.

About

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Show more...
CEO
Mr. John Charles Jacobs M.B.A.
Employees
1543
Country
US
ISIN
US6700024010

Listings